Fibrosis marker syndecan-1 and outcome in patients with heart failure with reduced and preserved ejection fraction

Circulation: Heart Failure

Volumn 7, Issue 3, 2014, Pages 457-462

  Tromp, Jasper ^a   Van Der Pol, Atze ^a   Klip, Ijsbrand T ^a   De Boer, Rudolf A ^a   Jaarsma, Tiny ^b   Van Gilst, Wiek H ^a   Voors, Adriaan A ^a   Van Veldhuisen, Dirk J ^a   Van Der Meer, Peter ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Fibrosis; Heart failure; Prognosis; Syndecan 1

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; SYNDECAN 1;

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FIBROSIS; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

FIBROSIS; HEART FAILURE; PROGNOSIS; SYNDECAN-1;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHRONIC DISEASE; COMORBIDITY; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; SURVIVAL RATE; SYNDECAN-1; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84902788077     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000846     Document Type: Article

References (20)

1. Schellings MW, Pinto YM, Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res. 2004;64:24-31.
2. Schellings MW, Vanhoutte D, van Almen GC, Swinnen M, Leenders JJ, Kubben N, van Leeuwen RE, Hofstra L, Heymans S, Pinto YM. Syndecan-1 amplifies angiotensin II-induced cardiac fibrosis. Hypertension. 2010;55:249-256.
3. Vanhoutte D, Schellings MW, Götte M, Swinnen M, Herias V, Wild MK, Vestweber D, Chorianopoulos E, Cortés V, Rigotti A, Stepp MA, Van de Werf F, Carmeliet P, Pinto YM, Heymans S. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation. 2007;115:475-482.
4. Lei J, Xue SN, Wu W, Zhou SX, Zhang YL, Yuan GY, Wang JF. Increased level of soluble syndecan-1 in serum correlates with myocardial expression in a rat model of myocardial infarction. Mol Cell Biochem. 2012;359:177-182.
5. Alexopoulou AN, Multhaupt HA, Couchman JR. Syndecans in wound healing, inflammation and vascular biology. Int J Biochem Cell Biol. 2007;39:505-528.
6. Meyer S, van der Meer P, van Deursen VM, Jaarsma T, van Veldhuisen DJ, van der Wal MH, Hillege HL, Voors AA. Neurohormonal and clinical sex differences in heart failure. Eur Heart J. 2013;34:2538-2547.
7. Jaarsma T, Van Der Wal MH, Hogenhuis J, Lesman I, Luttik ML, Veeger NJ, Van Veldhuisen DJ. Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure. Eur J Heart Fail. 2004;6:227-233.
8. Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ, Sanderman R, Hoes AW, van Gilst WH, Lok DJ, Dunselman PH, Tijssen JG, Hillege HL, van Veldhuisen DJ; Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) Investigators. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med. 2008;168:316-324.
9. van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HL. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61:1498-1506.
10. Kleijn L, Belonje AM, Voors AA, De Boer RA, Jaarsma T, Ghosh S, Kim J, Hillege HL, Van Gilst WH, van Veldhuisen DJ, van der Meer P. Inflammation and anaemia in a broad spectrum of patients with heart failure. Heart. 2012;98:1237-1241.
11. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:60-68.
12. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation. 2006;114:1572-1580.
13. Postmus D, van Veldhuisen DJ, Jaarsma T, Luttik ML, Lassus J, Mebazaa A, Nieminen MS, Harjola VP, Lewsey J, Buskens E, Hillege HL. The COACH risk engine: a multistate model for predicting survival and hospitalization in patients with heart failure. Eur J Heart Fail. 2012;14:168-175.
14. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11-21.
15. Tkachenko E, Rhodes JM, Simons M. Syndecans: new kids on the signaling block. Circ Res. 2005;96:488-500.
16. Alexopoulou AN, Multhaupt HA, Couchman JR. Syndecans in wound healing, inflammation and vascular biology. Int J Biochem Cell Biol. 2007;39:505-528.
17. Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M, Sato H. Cleavage of syndecan-1 by membrane type matrix metalloproteinase- 1 stimulates cell migration. J Biol Chem. 2003;278:40764-40770.
18. Kandalam V, Basu R, Moore L, Fan D, Wang X, Jaworski DM, Oudit GY, Kassiri Z. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation. 2011;124:2094-2105.
19. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520-530.
20. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670-679.